Virazole
(Ribavirin)ApprovedSmall molecule
Ribavirin is an antiviral medication used to treat certain viral infections, most commonly hepatitis C (often combined with other drugs) and severe respiratory syncytial virus (RSV) infection in hospitalized patients.[2] Virazole is currently approved and in use across 43 indications[4].[1]
Virazole is one of 1014 small molecule programs targeting Insulin resistance. It is currently in Approved.
43
Indications
517
Total Trials
2
Active Trials
1,013
Competitors
4
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 43 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Virazole
CConrado Roberto Hoffmann Filho
Approved
Adriamycin
GGynecologic Oncology Group
Preclinical
Megace
Bristol-Myers SquibbPreclinical
Zolymbus
AbbViePreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Acupan
YYonsei University
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Aquasol E
NNational Eye Institute (NEI)
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Neoadjuvant Therapy
SSun Yat-sen University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Hepatitis81 trials
Show 78 more trials
Efficacy of Nitazoxanide in the Treatment of Chronic Hepatitis C Virus (HCV)
Completed·—·Phase 2/3·NCT01276756·100 enrolled
Observational Cohort Study of Clinical Outcomes After Antiviral Therapy for Chronic Hepatitis C
Unknown status·—··NCT04071353·1,000 enrolled
Long-Term Therapy With Ribavirin for Chronic Hepatitis C
Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 4·NCT00001854·50 enrolled
Chronic Hepatitis C Treatment by Pegylated Interferon and Ribavirin in Naive Egyptian Patients (ANRS 1211)
Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 3·NCT00158496·100 enrolled
Hepatitis C46 trials
Show 43 more trials
Efficacy of Pegylated Interferon on Liver Fibrosis in Co-infected Patient With HIV and Hepatitis C
Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 3·NCT00122616·52 enrolled
Hepatitis C Antiviral Resistance in African-Americans
Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 3·NCT00038974·401 enrolled
Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV
Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 4·NCT01443923·4 enrolled
Treatment11 trials
Show 8 more trials
Chronic Hepatitis C Virus Infection6 trials
Show 3 more trials
37 more indications
Hepatitis C Virus Infection4 trials
Liver Transplant3 trials
Safety and Efficacy3 trials
Randomized2 trials
HCV Infection2 trials
Lassa fever2 trials
Hepatocellular Carcinoma2 trials
Hepatitis B2 trials
Pediatric1 trial
Liver Disease1 trial
Metastatic Melanoma1 trial
Interaction1 trial
Herpangina1 trial
Effect of Recombinant Human Interferon α-2b Spray on Herpangina
Completed·—·Phase 4·NCT03266601·668 enrolled
Oral1 trial
Effect of Xiaoer Jiebiao Oral Liquid on Hand-foot-mouth Disease
Completed·—·Phase 4·NCT02328651·24 enrolled
Cirrhosis1 trial
HCV1 trial
Response Modifier (Arabinoxylan Rice Bran/MGN-3/Biobran) With Interferon-Alpha for HCV
Completed·—·Phase 2·NCT02690103·37 enrolled
Hepatitis E Virus Infection1 trial
HIV-11 trial
Children1 trial
Hemorrhage1 trial
Immunodeficiency1 trial
Monotherapy1 trial
Interleukin1 trial
Trial1 trial
A Phase I/II Trial of Ribavirin (With Escalation) + Isoprinosine in Asymptomatic HIV-Viremic Patients
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000699·20 enrolled
Chronic Kidney Disease1 trial
End Stage Renal Disease (ESRD)1 trial
Boceprevir in End Stage Renal Disease (ESRD)
Withdrawn·—·N/A·NCT02112630
Unspecified4 trials
Show 1 more trial
12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF
Terminated·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 2·NCT02605304·7 enrolled
Regulatory
FDA Approval Timeline[5]
Dec 31, 1985
VIRAZOLE
NDA NDA018859
Jun 3, 1998
REBETOL
NDA NDA020903
Dec 3, 2002
COPEGUS
NDA NDA021511
Jul 29, 2003
REBETOL
NDA NDA021546
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Virazole drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Ribavirin. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Inosine-5'-Monophosphate Dehydrogenase 1 Inhibitor; RNA-Directed RNA Polymerase Inhibitor[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- CConrado Roberto Hoffmann Filho